quinazolines has been researched along with Complications of Diabetes Mellitus in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Charbonnel, B; Dejager, S; Schweizer, A | 1 |
| Chatziralli, IP; Sergentanis, TN | 1 |
| Suzuki, Y; Yamamoto, T | 1 |
| Johansen, OE; Neubacher, D; Patel, S; von Eynatten, M; Woerle, HJ | 1 |
| Alcaraz, A; Elhilali, M; Emberton, M; Hartung, R; Harving, N; Matzkin, H; Vallancien, G; van Moorselaar, J | 1 |
| Funk, G; Kornek, GV; Oehler, L; Scheithauer, W; Schwarz, C; Urbauer, E; Wenzel, C | 1 |
| Kather, H | 1 |
| Nishinaka, T; Yabe-Nishimura, C | 1 |
| Königstein, RP | 1 |
4 review(s) available for quinazolines and Complications of Diabetes Mellitus
| Article | Year |
|---|---|
Linagliptin. Avoid gliptins!
Topics: Biomarkers; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Hypersensitivity; Drug Interactions; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Immune System; Linagliptin; Pancreatitis; Patient Selection; Purines; Quinazolines; Risk Assessment; Risk Factors; Treatment Outcome | 2013 |
Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?
Topics: Adamantane; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Linagliptin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2013 |
Risk factors for intraoperative floppy iris syndrome: a meta-analysis.
Topics: Adrenergic alpha-1 Receptor Antagonists; Diabetes Complications; Doxazosin; Humans; Hypertension; Incidence; Intraoperative Complications; Iris; Iris Diseases; Odds Ratio; Phacoemulsification; Prazosin; Quinazolines; Risk Factors; Sulfonamides; Syndrome; Tamsulosin | 2011 |
Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme.
Topics: Aged; Angina, Unstable; Biomarkers; Blood Glucose; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Evidence-Based Medicine; Female; Glycated Hemoglobin; Hospitalization; Humans; Linagliptin; Male; Middle Aged; Myocardial Infarction; Patient Safety; Proportional Hazards Models; Prospective Studies; Purines; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Stroke; Treatment Outcome | 2012 |
6 other study(ies) available for quinazolines and Complications of Diabetes Mellitus
| Article | Year |
|---|---|
Reactive perforating collagenosis during erlotinib therapy.
Topics: Aged; Collagen Diseases; Diabetes Complications; Drug Eruptions; Erlotinib Hydrochloride; Humans; Male; Protein Kinase Inhibitors; Quinazolines; Skin Diseases | 2012 |
Age, comorbidity and hypertensive co-medication do not affect cardiovascular tolerability of 10 mg alfuzosin once daily.
Topics: Adrenergic alpha-Antagonists; Age Factors; Aged; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Complications; Drug Administration Schedule; Humans; Hypertension; Male; Middle Aged; Myocardial Ischemia; Quinazolines; Urination Disorders | 2006 |
Severe enteropathy associated with raltitrexed and oxaliplatin chemotherapy: report of two patients experiencing this rare, potentially lethal gastrointestinal adverse event.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Colonoscopy; Colorectal Neoplasms; Diabetes Complications; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Enterocolitis; Fatal Outcome; Female; Gastrointestinal Diseases; Humans; Lung Neoplasms; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Thiophenes | 2006 |
[Hypertensive therapy with prazosin. Concomitant cardiovascular, metabolic and respiratory diseases. Proven facts and potential aspects].
Topics: Adolescent; Adult; Arrhythmias, Cardiac; Cardiovascular Diseases; Diabetes Complications; Humans; Hypertension; Kidney; Lipids; Myocardial Infarction; Prazosin; Quinazolines; Respiratory Tract Diseases | 1984 |
EGF receptor-ERK pathway is the major signaling pathway that mediates upregulation of aldose reductase expression under oxidative stress.
Topics: Aldehyde Reductase; Animals; Cell Line; Cell Survival; Diabetes Complications; Diabetes Mellitus; ErbB Receptors; Flavonoids; Free Radical Scavengers; Humans; Hydrogen Peroxide; Mitogen-Activated Protein Kinases; Muscle, Smooth, Vascular; Oxidative Stress; Phthalazines; Protein Kinases; Quinazolines; Rats; RNA, Messenger; Signal Transduction; Tyrphostins; Up-Regulation | 2001 |
[Treatment of hypertension with prezosin in aged diabetics].
Topics: Aged; Blood Glucose; Diabetes Complications; Diabetes Mellitus; Diet Therapy; Female; Humans; Hypertension; Insulin; Middle Aged; Prazosin; Quinazolines; Sulfonylurea Compounds | 1978 |